Skip to main content
SpringerLink
Log in

ESC-Leitlinie Dyslipidämien: die 10 Kernbotschaften

Kritische Bewertung

Critical review of the ESC Guidelines 2019 for the management of dyslipidaemias in 10 key-messages

  • FORTBILDUNG -- ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Im letzten Jahr sind die neuen Leitlinien der European Society of Cardiology (ESC) für die Behandlung von Fettstoffwechselstörungen erschienen. Die Autoren dieses Beitrags kommentieren die 10 Key Messages aus der Zusammenfassung der Leitlinien.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference, Ian M Graham, Alison Halliday, Ulf Landmesser, Borislava Mihaylova, Terje R Pedersen, Gabriele Riccardi, Dimitrios J Richter, Marc S Sabatine, Marja-Riitta Taskinen, Lale Tokgozoglu, Olov Wiklund, ESC Scientific Document Group, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), European Heart Journal, ehz455, https://doi.org/10.1093/eurheartj/ehz455

  2. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387–2397.

    Google Scholar 

  3. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713–1722.

    Google Scholar 

  4. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronarysyndrome. N Engl J Med 2018;379:2097–2107.

    Google Scholar 

  5. Ridker PM et al. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. N Engl J Med. 2017 Apr 20;376(16):1527–1539

    Google Scholar 

  6. Langlois MR et al.; European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM. Clin Chem 2018;64:10061033.

    Google Scholar 

  7. Tsimikas S. A Test in Context: Lipoprotein(a). JACC 2017 (69): 692–711

    Google Scholar 

  8. Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, Willeit P, Young R, Surendran P, Karthikeyan S, Bolton TR, Peters JE, Kamstrup PR, Tybjaerg-Hansen A, Benn M, Langsted A, Schnohr P, Vedel-Krogh S, Kobylecki CJ, Ford I, Packard C, Trompet S, Jukema JW, Sattar N, Di Angelantonio E, Saleheen D, Howson JMM, Nordestgaard BG, Butterworth AS, Danesh J; European Prospective Investigation Into Cancer and Nutrition - Cardiovascular Disease (EPIC-CVD) Consortium. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol 2018;3:619627.

    Google Scholar 

  9. https://www.g-ba.de/downloads/83-691-541/AM-RL-III-Verordnungseinschr%C3%A4nkungen_2019-07-05.pdf

  10. Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Honarpour N, Wasserman SM, Ott BR; EBBINGHAUS Investigators. Cognitive function in a randomized trial of evolocumab. N Engl J Med 2017;377:633–643.

    Google Scholar 

  11. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019; 393: 407–15.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nephrocare Hamburg-Barmbek GmbH, Hebebrandstraße 6, D-22399, Hamburg, Deutschland

    Kai Toussaint &  Claudia Brückner

Authors
  1. Kai Toussaint
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Brückner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kai Toussaint.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toussaint, K., Brückner, C. ESC-Leitlinie Dyslipidämien: die 10 Kernbotschaften. MMW - Fortschritte der Medizin 162, 45–48 (2020). https://doi.org/10.1007/s15006-020-0523-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-020-0523-7

Keywords

Search

Navigation